癌症中的PHLDA2:从分子机制到治疗机会
Qingqing Wan1, Mi Zhang1, Wantao Chen1
1Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology; Shanghai Research Institute of Stomatology, Shanghai, China.
The Journal of pharmacology and experimental therapeutics
|September 11, 2025
概括
普莱克斯特林同源性类似域,A家族,成员2 (PHLDA2) 在癌症中充当瘤抑制剂和瘤基因. 这篇评论探讨了PHLDA2在亡,自和铁亡中的作用,提供了新的诊断和治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 普莱克斯特林同质类域,A家族,成员2 (PHLDA2) 是印记在染色体11p15.5.5上的一个基因.
- PHLDA2在癌症中表现出复杂的双重作用,同时作为瘤抑制剂和瘤基因.
研究的目的:
- 综合了解PHLDA2对瘤发生的机制性贡献的最新进展.
- 提供PHLDA2在各种癌症类型中的上下文依赖功能的全面分析.
- 突出PHLDA2作为诊断生物标志物和治疗点的新兴潜力.
主要方法:
- 综合PHLDA最近研究的文献综述2.2.
- 对PHLDA2在各种癌症类型和瘤微环境中的作用进行比较分析.
- 检查PHLDA2对亡,自和铁亡的调节.
主要成果:
- PHLDA2调节关键的细胞过程,包括亡,自和铁亡.
- 瘤微环境和癌症类型决定了PHLDA2的功能 (瘤原生与瘤抑制).
- 新的见解包括PHLDA2通过ALOX12相互作用和PI3K/AKT通路调节在铁中发挥的作用.
结论:
- PHLDA2的双重作用和翻译后修改为精确的癌症诊断和治疗提供了机会.
- 需要进一步的研究,以克服将PHLDA2发现转化为临床应用的挑战.
- PHLDA2代表了精确癌症医学的一个有前途的目标.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Cancer
53.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.5K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


